Skip to main content

Table 1 Evaluation of drug combinations for inhibition of HIV-1 in MT-2 cell culture.

From: The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study

Combinations

Analysis Method

 

Median-Effecta

(Combination Index)

MacSynergyb

(Synergy/Antagonism Volumes μM2%)

Isobologramc

(ADA, p value)

TFV+FTC

synergy (0.52 ± 0.08)

strong synergy (181 ± 30/-36 ± 10)

synergy (-0.37, 0.001)

TFV+EFV

synergy (0.51 ± 0.14)

strong synergy (267 ± 50/-13 ± 5)

synergy (-0.14, 0.027)

FTC+EFV

synergy (0.59 ± 0.11)

moderate synergy (90 ± 30/0 ± 10)

synergy (-0.23, 0.001)

TFV+FTC+EFV

synergy (0.56 ± 0.12)

NDd

ND

  1. a The drugs were mixed at 1:1 IC50 ratios. Definition of the degrees of synergy is described in Methods. The values are averages of more than three independent measurements.
  2. b Synergy/antagonism volumes were calculated at the 95% confidence level. Definition of the degrees of synergy is described in Methods.
  3. c Synergy is defined by a negative ADA (the average deviation from dose-wise additivity) value with p value ≤ 0.05.
  4. dND = not determined.
Back to article page

Retrovirology

ISSN: 1742-4690

Contact us